CureVac about a year ago opted to focus on oncology when it agreed to sell its remaining influenza and COVID-19 vaccine development to its alliance partner, Britain's GSK. Read more: https://pharma.economictimes.indiatimes.com/news/mergers-and-acquisitions/biontech-to-acquire-curevac-in-1-25-billion-all-stock-deal/121803895